• Repurposing Natural Compounds Against SARS-CoV-2 Main Protea

  2026-06-11

  Eskandari et al. (2022) systematically evaluated natural vitamins for their potential to inhibit SARS-CoV-2 main protease (3CLpro) and the spike protein receptor-binding domain (RBD) using molecular docking and dynamics. Their findings highlight the promise of accessible, safe compounds for antiviral therapeutics research, offering new directions for COVID-19 intervention strategies.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Precision Pr

  2026-06-10

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit enables flexible, high-yield synthesis of fluorescent RNA probes for advanced gene expression and hybridization assays. Its tunable Cy5-UTP incorporation and robust T7 transcription workflow empower researchers to optimize probe sensitivity and specificity for applications such as in situ hybridization and Northern blotting.

• Targeting the CaN/FoxO1/FABP4 Pathway in Atherosclerosis Pro

  2026-06-10

  This study reveals that SERCA2 dysfunction accelerates atherosclerosis by activating the calcineurin/FoxO1/FABP4 pathway, promoting macrophage foam cell formation. Inhibiting FABP4 pharmacologically or genetically corrects lipid metabolism, suggesting new therapeutic avenues for atherosclerotic disease.

• Aconitase Activity: Illuminating TCA Cycle Insights in Immun

  2026-06-09

  Discover how precise measurement of iron-sulfur protein aconitase activity with the Aconitase Activity Colorimetric Assay Kit is reshaping translational research at the intersection of mitochondrial metabolism, oxidative stress, and immunometabolic reprogramming. This thought-leadership article bridges mechanistic insight and strategic guidance for scientists seeking robust biomarkers and workflow reliability in the era of metabolic precision medicine.

• Mannosylated Cholesterol LNPs Enhance In Vivo mRNA Delivery

  2026-06-09

  This study introduces cholesterol-derived mannosylated polypeptide-forming lipid nanoparticles (LNPs) that actively target antigen-presenting cells (APCs) for efficient in vivo mRNA delivery. The findings demonstrate improved lymph node accumulation and transfection in dendritic cells, presenting a promising strategy to boost mRNA vaccine efficacy while reducing required doses.

• FH1 Small Molecule: Redefining Hepatocyte Maturity for Trans

  2026-06-08

  Explore how FH1, a leading small molecule, revolutionizes cultured hepatocyte function enhancement and bridges optogenetic gene control with next-generation liver cell models. This article offers new insights beyond protocol optimization, focusing on practical implications for advanced translational research.

• Fangchinoline Restores Lysosomal Biogenesis to Block H1N1 En

  2026-06-08

  The reference study identifies fangchinoline as a potent activator of TFEB-driven lysosomal biogenesis, disrupting H1N1 influenza virus entry by restoring lysosomal function. These findings highlight a novel host-directed antiviral strategy and underscore the importance of targeting lysosomal pathways in infectious disease research.

• Myeloid Tet2-IL-1β Axis Restricts Stress-Driven Colitis via

  2026-06-07

  This study reveals how myeloid-specific loss of TET2 limits intestinal inflammation by increasing IL-1β, which dampens catecholaminergic neuron-epithelial crosstalk and reduces enterochromaffin cell differentiation. These findings uncover a neuro-immune-epithelial circuit that modulates colitis severity, highlighting the impact of stress and epigenetic regulation in gut immunity.

• WNT Signaling Drives Cholangiocyte Proliferation After Bile

  2026-06-06

  The referenced study uncovers a β-catenin–dependent role for WNT signaling in promoting cholangiocyte proliferation following extrahepatic bile duct obstruction in mice. This mechanistic insight refines our understanding of cholangiopathies and suggests new experimental avenues for dissecting injury-induced biliary responses.

• Trelagliptin Succinate: Mechanistic Gateways for Translation

  2026-06-05

  This thought-leadership article explores Trelagliptin succinate (SYR-472 succinate) as a paradigm-shifting tool for translational diabetes and metabolic research. It synthesizes mechanistic insights—centered on DPP-4 inhibition, PI3K/Akt/GLUT4 signaling, and emerging anti-inflammatory and bone-protective actions—with actionable guidance for experimental design and strategic pipeline expansion. Drawing from recent literature, validated protocols, and comparative product intelligence, it demonstrates how APExBIO’s Trelagliptin succinate empowers researchers to bridge foundational mechanistic studies with next-generation clinical translation.

• Berberine Hydrochloride Counters Estrogen Deficiency Bone Lo

  2026-06-05

  A recent study reveals that berberine hydrochloride mitigates bone loss driven by estrogen deficiency by promoting intestinal tuft cell expansion via butyrate-GPR41 signaling. This mechanistic insight highlights the gut-bone axis as a promising target for postmenopausal osteoporosis research and suggests new directions for osteoimmune intervention.

• AMPK’s Dual Role in Autophagy Under Energy Stress Redefined

  2026-06-04

  This study overturns the prevailing model of AMPK as a universal autophagy activator, revealing instead that AMPK suppresses autophagy induction via ULK1 inhibition during glucose starvation, while simultaneously safeguarding autophagy machinery integrity. These findings reshape our understanding of energy stress responses and have significant implications for research into autophagy, vesicle trafficking, and cellular survival under metabolic stress.

• Gentamycin Sulfate in Resistance Research: Protocols & Optim

  2026-06-04

  Gentamycin Sulfate stands out as a benchmark aminoglycoside antibiotic for high-fidelity modeling of Gram-negative bacterial resistance and ribosome function. This guide delivers workflow enhancements, troubleshooting insights, and real-world applications grounded in the latest transmission dynamics research.

• EZH2 Inhibition Targets HPV-Driven Cervical Cancer Progressi

  2026-06-03

  This study demonstrates that EZH2 inhibitors, including EPZ-6438, suppress HPV-associated cervical cancer cell proliferation by downregulating oncogenic pathways and restoring tumor suppressor activity. These findings suggest a promising, less toxic alternative to conventional chemotherapy for HPV-driven malignancies.

• Ertugliflozin (PF-04971729): Precision SGLT2 Inhibition in R

  2026-06-03

  Ertugliflozin (PF-04971729) delivers unparalleled selectivity in SGLT2 inhibition, empowering metabolic and cardiovascular disease modeling with reproducible results. This guide translates the latest cardiometabolic research into actionable protocols and troubleshooting insights for advanced experimental workflows.

16451 records 1/1097 page Next 12345 下5页 Last page